Skip to main content
. 2022 Mar 8;41(5):751–760. doi: 10.1007/s10096-022-04415-6

Table 4.

Antimicrobial treatment of bacteraemic patients (n = 77)

Antimicrobial agent Initial agent (n = 76) 2nd agent (n = 70) 3rd agent (n = 45) 4th agent (n = 21) 5th agent (n = 6)
Cefuroxime 66 (86.8%) 1 (1.4%) 5 (11.1%) - 1 (16.7%)
Cefuroxime + other agenta 3 (3.9%) 5 (7.1%) 1 (2.2%) 1 (4.8%) -
Ceftriaxone 2 (2.6%) 4 (5.7%) 4 (8.9%) 4 (14.3%)b -
Cefalexin - 3 (4.3%) 1 (2.2%)c 1 (4.8%) -
Penicillins 2 (2.6%) 34 (48.6%) 22 (48.9%) 9 (42.9%) 3 (50%)
     Benzylpenicillin - 11 (15.7%) 4 (8.9%) 4 (19.0%)d -
     Phenoxymethylpenicillin - - 4 (8.9%) 1 (4.8%) 2 (33.3%)d
     Ampicillin - 7 (10.0%)d 1 (2.2%) - -
     Amoxicillin 1 (1.3%) 7 (10.0%) 12 (26.7%)c 2 (9.5%) 1 (16.7%)
     Amoxicillin with clavulanic acid - 5 (7.1%) 1 (2.2%) 2 (9.5%) -
     Cloxacillin 1 (1.3%) 4 (5.7%)e - -
Broad-spectrumf 4 (5.3%) 11 (15.7%) 5 (11.1%)d 2 (9.5%) 2 (33.3%)
Otherg 1 (1.3%) 12 (17.1%) 7 (15.6%)h 4 (19.0%) -

aOther agent = clindamycin, metronidazole, tobramycin, moxifloxacin, and vancomycin

bThree cases combined with (1) clindamycin (2) piperacillin-tazobactam and (3) linezolid

cOne case combined with metronidazole

dOne case combined with levofloxacin

eOne case combined with vancomycin

fImipenem, meropenem, and piperacillin-tazobactam

gCiprofloxacin, clindamycin, gentamicin, levofloxacin, nitrofurantoin, sulfa-trimethoprim, and vancomycin

hIn one case levofloxacin combined with vancomycin